outperform price
downgrad in-lin pt
matter call fair assum
debat robust downgrad in-lin
see risk upsid surpris fairli balanc
current level new pt equat price-to-earnings
 ev/ebitda equat return current
level pleas join us webinar et
morn go medtech/tool outlook
thesi see link webinar slide
call challeng curv ball
thrown compani microarray/dtc declin
china pop-gen project delay look toward
think compani like start year
conserv outlook debat whether revenue
guid could st whether
price find hard differenti number
think much await pop-gen project larg expect
st dont expect major new product cycl
chang dynam near term huge
fan fundament secular growth compani
longer term current valuat caus us move
project announc could potenti upsid catalyst
downsid risk delay pop gen project
lead slower revenue ramp
link et webinar click
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
wait pop seq d/g in-line valuat
growth yr om remain strong
array dont get wors
china lt sequenc bounc back
year perf vs xlv u/p
read stock chart tough yr growth slow
tough year growth never materi popseq delay hw deliv yr miss lower guidanc
pre-a
ahead st
rev/growth
ep mix due light
instrument weak
overhaul forecast
ep beat
chart factset evercor isi
plenti hw came seq consum weak dtc declin
perfect storm hw
popseq big part seq consum rev
came mm light vs expect
lt sequenc came light partli due china
declin lsd vs hsd histor
think initi guid could rang st potenti teen bull case
u/g ht instr
start ramp
seq consum key sensit model
growth hing popseq lt sequenc pull-through like
return normal rang china clinic
debat ep like stwe think opex like step delay spend catch
mm
incent comp
push
revenue miss
expect come
back
weigh margin
interest
lack gain
debat lt bull case compani could dd grower driven popgen clinic
sequenc rev clinic go
downgrad in-lin rate pt tsr
in-lin w/ st model rev
ep
pt impli price-to-earnings premium vs current
pt equat price-to-earnings
premium target price-to-earnings
repres
basi equat yield
ev/ebitda basi pt equat
net cash posit believ could potenti
sourc upsid
conclus light ilmn challeng
microarray/dtc declin china
 pop-gen project delay expect
compani guid conserv
rang st driver pop-gen project
larg expect st think step-up
opex limit ep huge fan
secular growth co longer term
current valuat caus us move
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin decemb
analyst luke sergott vijay kumar primarili respons prepar research report attest follow view
opinion render research report reflect person view subject compani issuer part
research analyst compens directli relat specif recommend view research report
